Search Medical Condition
Please enter condition
Please choose location from dropdown

Jossigny, France Clinical Trials

A listing of Jossigny, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (24) clinical trials

Prospective Single-arm Multi Centre Observations Ultimaster Des Registry

All consecutive patients suitable for treatment with DES according to hospital routine practice in centres across the world that agree to participate in the e-ULTIMASTER registry will be treated with Ultimaster DES. Secondary objectives Evaluation of worldwide utilization of DES, Detection of rare events in representative patient population, identification of ...

Phase N/A

0.0 miles

Learn More »

Clinical and Device Functional Assessment of Real World ICD Patients

For these reasons, it is very important to observe the clinical practice on a large variety of centers and countries, with the objective to collect long term safety and performance data in patients undergoing ICD/CRT-D device implantation (first implant, replacement or upgrade). The safety and performance of the ICDs can ...

Phase N/A

0.0 miles

Learn More »

Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .

Multicenter prospective phase II study evaluating regorafenib in older patients with metastatic colorectal cancer

Phase

0.0 miles

Learn More »

EURopean Study on Encephalitis in Intensive CAre

Prospective observational multicenter study in European ICUs. All patients admitted to the ICU for probable or confirmed Acute encephalitis (2013 IDSA - Infectious Disease Society of America criteria) will be included. Factors associated with a poor prognosis will be identified by multivariate analysis using a logistic regression.

Phase N/A

0.0 miles

Learn More »

Follow-up of HBsAg Inactive Carriers Study

The definition of HBs antigen (HBsAg) inactive carrier status has evolved during time. We spoke first from HBsAg" healthy carrier ", then from " asymptomatic carrier ", last from HBsAg" inactive carrier ". This definition continue to be not totally consensual. A very low viral load (< 2000 UI/ml) or ...

Phase N/A

0.0 miles

Learn More »

A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real Life

This is a prospective, non-interventional and pharmaco-epidemiological study of participants with IBD. The study will provide the real-life data of treatment effectiveness and safety of vedolizumab in adult participants with UC or CD. The study will enroll approximately 300 participants. All participants will be enrolled in one observational group: Vedolizumab ...

Phase N/A

0.0 miles

Learn More »

End Of Life in the Critically Ill patiEnt

More than 20% of deaths occur in hospital after a stay in intensive care units; up to half of them happens as result of a treatment limitation. Ensuring end-of-life quality is important, not only because is a moral duty of all caregivers, but also to prevent negative effects in close ...

Phase N/A

0.0 miles

Learn More »

Central Apnea in Patients Receiving Ticagrelor

all patients with a left ventricular ejection fraction superior or equal to 50% less than 2 years after an acute coronary event and receiving ticagrelor will undergo a sleep polygraphy the main objective of the study will be to look for central sleep apnea

Phase N/A

2.38 miles

Learn More »

National Cohort of Children Born to HIV-positive Mothers

The goal of the CO11 national cohort is to provide with CO1 a wider surveillance system to monitor changes in the rate of mother to child transmission and preventive practices in France and especially to identify the occurrence of toxicity in children exposed perinatally to antiretroviral drugs. The CO11 EPF ...

Phase N/A

3.04 miles

Learn More »

ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial

During a run-in period : Spironolactone will be initially administered per os at a 25 mg dose per two days in practice after the session, three times per week Patients will be randomized (spironolactone vs. placebo) and titrated over one month to a maximum single dose of 25 mg/d However ...

Phase

3.04 miles

Learn More »